Holen Sie sich die Stockscreener-App
254.87
1.82%
-5.235
Schlusskurs vom Vortag:
$260.10
Offen:
$257.07
24-Stunden-Volumen:
297.94K
Relative Volume:
0.17
Marktkapitalisierung:
$34.10B
Einnahmen:
$4.29B
Nettoeinkommen (Verlust:
$577.22M
KGV:
60.56
EPS:
4.2086
Netto-Cashflow:
$641.34M
1W Leistung:
-4.50%
1M Leistung:
+16.50%
6M Leistung:
-21.08%
1J Leistung:
-47.03%
1-Tages-Spanne:
$254.51
$261.98
1-Wochen-Bereich:
$254.00
$272.08
52-Wochen-Spanne:
$197.81
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
254.87 | 34.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
523.00 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.20 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.04 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.94 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.37 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
ALNY Maintained by Jefferies -- Price Target Raised to $260 - GuruFocus
Alnylam at Wells Fargo conference: TTR growth stays on track - Investing.com
Alnylam at Wells Fargo conference: TTR growth stays on track By Investing.com - Investing.com UK
Alnylam Pharmaceuticals, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Onpattro Market Analysis Reveals Trends in Changing Industry Demand - openPR.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A 39% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
Alnylam Pharmaceuticals (ALNY) Could Be 39% Undervalued On Fresh ESC 2026 Data - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech - ChartMill
ALNY Stock Climbs As Analysts Turn Bullish After ESC Data - StocksToTrade
ALNY Stock Rebounds As Analysts Back RNAi Momentum - timothysykes.com
ALNY Stock Rebounds As Analysts Back RNAi Pipeline Strength - StocksToTrade
Alnylam Pharmaceuticals Inc Stock (ALNY) Moved Up by 7.90% on Sep 2: Facts Behind the Movement - tradingkey.com
Alnylam Pharmaceuticals Gains as Investors Digest Fresh ESC Data and Upcoming Conference Appearances - Moomoo
Alnylam Pharmaceuticals gains as investors digest fresh ESC data and upcoming conference appearances - Quiver Quantitative
Alnylam to Webcast Presentations at Upcoming September Investor Conferences - Business Wire
ALNY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $455 - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY) - The Globe and Mail
Expanded RNAi Cardio Data Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY) - simplywall.st
Alnylam stock maintained at Buy by TD Cowen on silencing data - Investing.com Canada
Alnylam Pharmaceuticals (ALNY) Investor Outlook: Exploring a 56% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case (ALNY:NASDAQ) - Seeking Alpha
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings - Yahoo Finance
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today - Sahm
Alnylam drops as AstraZeneca posts full trial results for failed heart drug - Seeking Alpha
Why Everyone Is Watching Alnylam Pharmaceuticals (ALNY) Today - simplywall.st
ALNY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alnylam Pharmaceuticals, Inc. - GlobeNewswire
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026 - Business Wire
Is Alnylam (ALNY) Turning Expanded HELIOS-B and Zilebesiran Data Into Durable Cardiovascular Leadership? - Yahoo Finance
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week - AOL.com
Silvant Capital Management LLC Takes $5.46 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Wealthfront Advisers LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
NewEdge Wealth LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Biotech Is Booming, But These 2 Stocks Missed the Memo - Sahm
Danske Bank A S Takes $19.43 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & - GlobeNewswire
Lowered TTR Sales Outlook And Legal Probe Might Change The Case For Investing In Alnylam (ALNY) - simplywall.st
Bragar Eagel & Squire, P.C. is Investigating Alnylam - GlobeNewswire
Securities Fraud Investigation Into Alnylam - GlobeNewswire
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to "Strong-Buy" at BMO Capital Markets - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Worthy of Investor Attention - ChartMill
Mitsubishi UFJ Asset Management Co. Ltd. Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
NewEdge Advisors LLC Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
E Fund Management Co. Ltd. Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
(NASDAQ: ALNY): Investigation Launched Into Alnylam Pharmaceuticals, Inc. by Kessler Topaz Meltzer & Check, LLP - Barchart.com
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - WBOC TV
NASDAQ: ALNY: Kessler Topaz Meltzer & Check, LLP Launches Investigation Into Alnylam Pharmaceuticals, Inc. - NewMediaWire
Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today - Quiver Quantitative
Alnylam initiated an outperform at BMO on RNAi pipeline - Seeking Alpha
BMO Capital Markets Initiates Coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For We - Benzinga
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Sale |
299.18 |
3,830 |
1,145,853 |
1,582 |
0.45%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):